Global PD-1 and PD-L1 Inhibitors Market 2019-2023 | Strong Pipeline to Boost Growth
Globally, the prevalence of cancer has seen a significant rise in recent
years, and the global oncology therapeutics market has witnessed the
approval of various novel therapies. The gap between the demand and
supply of these therapies has resulted in a substantial unmet need,
which has created an opportunity for vendors to conduct a study on drugs
such as PD-1 and PD-L1 inhibitors. With an increase in cases of cancer,
various companies are researching on developing novel PD-1 and PD-L1
inhibitors to capture the vast unmet need, and the market has witnessed
the approval of these drugs in recent years. The increasing approvals of
these inhibitors for the treatment of various cancer indications are
expected to capture the huge unmet need, which is expected to add
significant value to the global PD-1 and PD-L1 inhibitors market during
the forecast period.
Global PD-1 and PD-L1 Inhibitors market: Strong Pipeline
The global PD-1 and PD-L1 inhibitors market witnesses the presence of various large pharmaceutical players with novel therapies in the pipeline for the treatment of various types of cancer. The superior efficacy of approved PD-1 and PD-L1 inhibitors has led to various companies stepping forward to research more advanced therapies to treat multiple cancer indications. As a result, the pipeline of these inhibitors is increasing, with highly promising therapies in the late stages of clinical trials. The approved treatments such as OPDIVO, KEYTRUDA, and IMFINZI are also being studied in clinical trials for multiple cancer indications, owing to their high efficacy in blocking PD-1 and PD-L1 signaling pathway for cancer cells. Thus, with such benefits, the market is expected to showcase a positive outlook during the forecast period.
Global PD-1 and PD-L1 Inhibitors market:
Segmentation analysis
This market research report segments the global PD-1 and PD-L1 Inhibitors market by application (solid tumors, blood-related tumors) and geographical regions (North America, Europe, Asia, ROW).
The North American region led the market in 2018 with a market share close to 52%, followed by Europe, Asia, and ROW respectively. However, during the forecast period, the European region is expected to register the highest incremental growth, followed by ROW.
Global PD-1 and PD-L1 Inhibitors market: Strong Pipeline
The global PD-1 and PD-L1 inhibitors market witnesses the presence of various large pharmaceutical players with novel therapies in the pipeline for the treatment of various types of cancer. The superior efficacy of approved PD-1 and PD-L1 inhibitors has led to various companies stepping forward to research more advanced therapies to treat multiple cancer indications. As a result, the pipeline of these inhibitors is increasing, with highly promising therapies in the late stages of clinical trials. The approved treatments such as OPDIVO, KEYTRUDA, and IMFINZI are also being studied in clinical trials for multiple cancer indications, owing to their high efficacy in blocking PD-1 and PD-L1 signaling pathway for cancer cells. Thus, with such benefits, the market is expected to showcase a positive outlook during the forecast period.
This market research report segments the global PD-1 and PD-L1 Inhibitors market by application (solid tumors, blood-related tumors) and geographical regions (North America, Europe, Asia, ROW).
The North American region led the market in 2018 with a market share close to 52%, followed by Europe, Asia, and ROW respectively. However, during the forecast period, the European region is expected to register the highest incremental growth, followed by ROW.
Comments
Post a Comment